SCN8A and epilepsy: The results of this study and previous evidence for the role of noradrenergic modulation in SCN8A-associated epilepsy, provide support for the continued investigation of the potential of CVD and other β-adrenergic receptor blockers as treatments for SCN8A-associated epilepsy.